Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-06-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine whether a larger dosage of estrogen than the one used today will secure the development of a normal sized uterus and increase the strength of the bones in girls and young women with Turner syndrome.

The purpose is also to evaluate whether aortic dilatation is present in this group of patients, and if the estrogen dosage will influence the emotional well-being and self-esteem of the patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hormone Replacement Therapy to Treat Turner Syndrome

NCT00013546

Osteoporosis Turner's Syndrome

COMPLETED PHASE2

Turner And Klinefelter Treatment Target Study

NCT04803474

Klinefelter Syndrome Turner Syndrome

UNKNOWN

Effects of Adrenal Androgens on Gender-typed Behavior in Girls With Turner Syndrome

NCT05346159

Turner Syndrome

COMPLETED

Klinefelter Syndrome and Testosterone Treatment in Puberty

NCT06294990

Klinefelter Syndrome

RECRUITING PHASE4

Pubertal Induction in Individuals With Hypogonadism

NCT02871986

Primary Amenorrhoea Hypothalamic Amenorrhoea Hypogonadotrophic Hypogonadism +3 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Turner syndrome is a common chromosomal disorder with only one X-chromosome or partial deletions in one X-chromosome in all or some of the cell-lines in the body. Appr. 18 girls/year are being born with the syndrome in Denmark. The syndrome is mostly known for reduced final height and the lack of pubertal development with infertility, but it is also known for diseases influencing other parts of the body like the heart with the risk of development of aortic dilatation and subsequently dissection with the risk of rupture, profuse bleeding and sudden death. Reduced bone strength and increased risk of bone fracture are also features of the syndrome. Treatment with growth hormone and female sex-hormones are well-established treatments.

Girls and young women with Turner syndrome ages 10 to 21 years will participate. The girls ages 15 to 21 years will randomly and double blindly receive treatment with either 2 mg or 4 mg estrogen for 5 years. Yearly examinations with blood tests, physical examinations, questionnaires, ultrasound and MR-scan of the internal female genitalia, DEXA-scan of the bones and MR-scan of the heart will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Turner Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

4 mg estradiol

Group Type ACTIVE_COMPARATOR

estradiol

Intervention Type DRUG

tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years

2 mg estradiol

Group Type PLACEBO_COMPARATOR

estradiol

Intervention Type DRUG

tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

estradiol

tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Verified Turner syndrome
* Ages 10-25 years

Exclusion Criteria

* Contraindications to the MR-scan
* Contraindications to the trial medication
* Severe or chronic sickness with impact on the parameters of the study or incompatibility with the trial medication
* Intake of medications with interactions with trial medication

Minimum Eligible Age

10 Years

Maximum Eligible Age

25 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No